|
|
![]() |
![]() |
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
|||||||||||||||||||||||||||||||||||||||||||||
| 1 | Conditions listed in this trial | ||||
| Deep Venous Thrombosis | |||||
| 2 | Additional conditions recognized in this trial | ||||
| Thrombosis | |||||
| Venous Thrombosis | |||||
| 3 | More general conditions related to this trial | ||||
| Cardiovascular Diseases | |||||
| Embolism and Thrombosis | |||||
| Vascular Diseases | |||||
| 4 | Interventions listed in this trial | ||||
| unfractionated heparin | |||||
| Tinzaparin (Leo) | |||||
| 5 | Additional drug interventions recognized in this trial | ||||
| Calcium heparin | |||||
| Heparin | |||||
| Heparin, Low-Molecular-Weight | |||||
| Tinzaparin | |||||
| 6 | More general drug interventions related to this trial | ||||
| Anticoagulants | |||||
| Cardiovascular Agents | |||||
| Fibrin Modulating Agents | |||||
| Fibrinolytic Agents | |||||
| Hematologic Agents | |||||
| Molecular Mechanisms of Pharmacological Action | |||||
| Pharmacologic Actions | |||||
| Therapeutic Uses | |||||
| 7 | Sponsors listed in this trial | ||||
| Aalborg Hospital | |||||
| Aalborg University | |||||